(born June 1, 1964) is an American scientist at Yale University.
As the Lewis B.
Cullman Professor of Molecular, Cellular and Developmental Biology, Crews also holds joint appointments in the departments of Chemistry and Pharmacology.
He currently serves as an Editor of Cell Chemical Biology and is the Executive Director of the Yale Center for Molecular Discovery.
His research interests focus on Chemical Biology, particularly on controlled proteostasis, which has led to the development of the FDA approved anti-cancer drug Carfilzomib (Kyprolis®).